Digoxin Dosing Calculator
Calculate digoxin loading and maintenance doses from weight, renal function, and lean body mass.
Calculator
Adjust values & calculateFormula
Volume of distribution (Vd) is calculated using the Jusko-Koup equation adjusted for lean body mass. Total body stores (TBS) equal the desired concentration times Vd. Loading dose equals TBS adjusted for bioavailability (70% oral, 100% IV). Maintenance dose replaces the daily elimination fraction. Creatinine clearance is estimated via Cockcroft-Gault.
Last reviewed: January 2026
Worked Examples
Example 1: Atrial Fibrillation Rate Control Dosing
Example 2: Heart Failure Patient with Renal Impairment
Background & Theory
The Digoxin Dosing Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Digoxin Dosing Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Formula
Vd = (226 + 298 x CrCl/(29.1 + CrCl)) x LBM/70 | Loading = Css x Vd | Maintenance = TBS x Daily Loss%
Volume of distribution (Vd) is calculated using the Jusko-Koup equation adjusted for lean body mass. Total body stores (TBS) equal the desired concentration times Vd. Loading dose equals TBS adjusted for bioavailability (70% oral, 100% IV). Maintenance dose replaces the daily elimination fraction. Creatinine clearance is estimated via Cockcroft-Gault.
Worked Examples
Example 1: Atrial Fibrillation Rate Control Dosing
Problem: A 65-year-old male (70 kg, 170 cm) with atrial fibrillation needs digoxin for rate control. Serum creatinine: 1.2 mg/dL. Target level: 1.0 ng/mL.
Solution: LBM (male) = 50 + 2.3 x ((170/2.54) - 60) = 50 + 2.3 x 6.93 = 65.9 kg\nCrCl = ((140-65) x 70) / (72 x 1.2) = 5250/86.4 = 60.8 mL/min\nVd = (226 + 298 x 60.8/(29.1+60.8)) x 65.9/70 = (226 + 201.5) x 0.941 = 402.5 L\nTBS = 1.0 x 402.5 = 402.5 mcg\nLoading IV = 0.403 mg (give 0.2 mg, then 0.1 mg x2)\nDaily Loss = ~25%\nMaintenance oral = ~0.18 mg/day\nNearest tablet: 0.1875 mg (3/4 of 0.25 mg tab)
Result: Loading: 0.4 mg IV divided | Maintenance: 0.1875 mg oral daily | Predicted SS: ~1.0 ng/mL
Example 2: Heart Failure Patient with Renal Impairment
Problem: A 78-year-old female (55 kg, 157 cm) with heart failure. Serum creatinine: 1.8 mg/dL. Target level: 0.7 ng/mL.
Solution: LBM (female) = 45.5 + 2.3 x ((157/2.54) - 60) = 45.5 + 2.3 x 1.8 = 49.6 kg\nCrCl = ((140-78) x 55) / (72 x 1.8) x 0.85 = 3410/129.6 x 0.85 = 22.4 mL/min\nVd = (226 + 298 x 22.4/(29.1+22.4)) x 49.6/70 = (226 + 129.6) x 0.709 = 252.0 L\nTBS = 0.7 x 252.0 = 176.4 mcg\nLoading IV = 0.176 mg\nReduced CrCl means slower elimination: ~15% daily loss\nMaintenance = 0.176 x 0.15 / 0.7 = 0.038 mg oral = 0.0625 mg every other day
Result: Loading: 0.175 mg IV divided | Maintenance: 0.0625 mg oral every other day | Monitor levels closely
Frequently Asked Questions
How is the digoxin loading dose calculated from patient parameters?
The digoxin loading dose is calculated by first determining the volume of distribution, which depends on lean body mass and renal function. The volume of distribution in liters is estimated using the Jusko-Koup equation: Vd = (226 + 298 x CrCl / (29.1 + CrCl)) adjusted for lean body mass. The total body stores needed are then calculated by multiplying the desired serum concentration in nanograms per milliliter by the volume of distribution in liters. For IV administration, the loading dose equals the total body stores since bioavailability is 100 percent. For oral tablets, the dose is divided by 0.7 to account for 70 percent bioavailability. The loading dose is typically administered in divided doses: half the total dose initially, then one quarter at 6 to 8 hours, and the final quarter at 6 to 8 hours later, to reduce the risk of toxicity from rapid administration.
Why is lean body mass used instead of total body weight for digoxin dosing?
Digoxin is highly lipophobic and distributes primarily into lean tissue, skeletal muscle, and organs rather than adipose tissue. Using total body weight in obese patients would overestimate the volume of distribution and result in supratherapeutic doses that increase toxicity risk. Lean body mass provides a more accurate estimate of the tissue compartment where digoxin actually distributes. The Devine formula is commonly used to estimate lean body mass: for males it equals 50 kg plus 2.3 kg per inch over 5 feet, and for females it equals 45.5 kg plus 2.3 kg per inch over 5 feet. In significantly obese patients where total body weight exceeds 120 percent of ideal body weight, an adjusted body weight using 40 percent of the excess weight is used for creatinine clearance estimation while lean body mass is used for volume of distribution calculations.
What is the therapeutic range for digoxin and why does it differ by indication?
The therapeutic range for digoxin varies based on the clinical indication. For heart failure, the DIG trial and subsequent analyses demonstrated that serum digoxin concentrations of 0.5 to 0.9 ng/mL provide optimal benefit with reduced mortality, while levels above 1.0 ng/mL were associated with increased mortality despite symptom improvement. For atrial fibrillation rate control, higher levels between 0.8 and 2.0 ng/mL may be needed to achieve adequate ventricular rate reduction, though current guidelines recommend targeting the lower end of this range. The narrow therapeutic index of digoxin means that the toxic concentration of approximately 2.0 ng/mL is only about twice the lower therapeutic level. This narrow margin makes careful dosing, monitoring, and awareness of drug interactions and electrolyte abnormalities essential for safe digoxin use.
How does renal function affect digoxin dosing and elimination?
Renal function is the single most important determinant of digoxin maintenance dosing because approximately 60 to 80 percent of digoxin is eliminated unchanged by the kidneys through glomerular filtration and tubular secretion. The remaining 20 to 40 percent undergoes hepatic metabolism and biliary excretion. In patients with reduced creatinine clearance, digoxin elimination is significantly prolonged, leading to accumulation and potential toxicity if doses are not reduced. For a patient with normal renal function and a creatinine clearance of 100 mL/min, the digoxin half-life is approximately 36 to 48 hours. In a patient with severe renal impairment and creatinine clearance of 20 mL/min, the half-life may extend to 4 to 6 days. Digoxin Dosing Calculator uses the Cockcroft-Gault equation to estimate creatinine clearance and adjusts both the volume of distribution and daily maintenance dose accordingly.
What is the Cockcroft-Gault equation and why is it used for digoxin dosing?
The Cockcroft-Gault equation estimates creatinine clearance from serum creatinine, age, weight, and sex: CrCl = ((140 minus age) times weight in kg) divided by (72 times serum creatinine in mg/dL), multiplied by 0.85 for females. Despite the availability of newer GFR estimation equations like CKD-EPI, the Cockcroft-Gault equation remains the standard for drug dosing because most pharmacokinetic studies that established drug dosing guidelines used this equation. It provides creatinine clearance rather than GFR, and these values are not interchangeable. Creatinine clearance overestimates GFR because creatinine is both filtered and secreted by the tubules. For digoxin specifically, creatinine clearance correlates well with actual digoxin renal clearance. When using this equation, the weight input should be adjusted body weight for obese patients and actual body weight for non-obese patients.
What are the signs and symptoms of digoxin toxicity?
Digoxin toxicity manifests across multiple organ systems with a wide range of symptoms. Cardiac symptoms are the most dangerous and include virtually any arrhythmia, with the most characteristic being paroxysmal atrial tachycardia with AV block, bidirectional ventricular tachycardia, and new onset of irregular rhythm in a previously regular pattern. Gastrointestinal symptoms include nausea, vomiting, anorexia, and abdominal pain, often occurring as early warning signs before cardiac toxicity. Neurological symptoms include confusion, drowsiness, dizziness, headache, and the classic visual disturbance of yellow-green halos around lights called xanthopsia. Risk factors that predispose to toxicity at therapeutic levels include hypokalemia, hypomagnesemia, hypercalcemia, hypothyroidism, advanced age, renal dysfunction, and drug interactions with amiodarone, verapamil, and quinidine.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy